Evicenter
P&T meetings

SKY-0515

Huntington's disease

Last updated
211 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

3 evidence topics · 3 sources

Pooled analyses across disease stage and dose

“This means we can’t yet see whether the drug could have different effects at different stages of HD, or if a higher dose has a stronger effect.” (opens the source at this quote in a new tab)

Baseline severity imbalance between extension dose groups

“Based on the CAP scores, the 9 mg cohort was represented by more severe participants compared to 4 mg cohort.” (opens the source at this quote in a new tab)

Dose-dependent biomarker response

“Participants switching from 3 mg to 4 mg showed incrementally an ~10% decrease, as expected.” (opens the source at this quote in a new tab)

Subgroup efficacy results by stage, CAG repeat length, or dose

No evidence found.